Embed Size (px)
Citation preview
Conference chairs:Andrew Jack, Pharmaceuticals Correspondent, Financial Times
Pete Mooney, Global Life Sciences & Healthcare Industry Leader, Deloitte
Speakers include:Mark Becker, Career Healthcare Analyst, Fidelity Worldwide Investments
Frances Cloud, Managing Director, Pharmacloud
Panos Kanavos, PhD, Reader in International Health Policy, Deputy Director, LSE Health
Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB
Professor Guido Rasi, Executive Director, European Medicines
Sir Michael Rawlins, Chairman, National Institute for Health and Clinical Excellence (NICE)
Dr Moncef Slaoui, Chairman, Research & Development, GSK
Ulf Wiinberg, Chief Executive Officer, Lundbeck A/S
For more information and to register:
www.ft-live.com/pharmabio
FT Global Pharmaceutical and Biotechnology Conference 2012
In Association with: Lead Sponsor:
Value at risk? The role for life sciences in the new healthcare era4-5 December 2012 | The Grange City Hotel, London
The FT Global Pharmaceuticals and Biotechnology Conference is renowned as the premier gathering for senior life science executives, industry leaders, payors and financers from around the world, with over 350 attendees participating at the 2011 event.
We are delighted to announce details of this year’s conference taking place on 4 & 5 December in London. The FT Global Pharmaceutical and Biotechnology Conference 2012 will explore the key issues facing the global life science industry to include the transition to value based pricing and the demands of real world evidence, and how forward looking companies are refining their strategies, building capabilities and transforming their operating models to stay head of the game.
Who should attend
• Pharmaceutical and biotechnology companies• Medical devices, instrumentation and diagnostics companies• Health insurers, government payors and private health service providers• Regulatory agencies and health technology assessment bodies• Healthcare financiers and investors• Data analytics and health informatics providers
Topics to be discussed
• Value based pricing - balancing innovation and affordability• Real world evidence - capturing the value of pharma• New pathways to growth - innovating the operating model• Reconfiguring the supply chain for a patient centred world• Social media and the life sciences industry• Emerging markets: Low-income countries – philanthropy or profit?
Sponsorship Opportunities
Take advantage of this unique opportunity to demonstrate your presence amongst this exclusive gathering of leading executives, government decision makers and investors from around the world.
For more information on the range of packages available, please contact Gigs Thoukidides on +44 (0)20 7873 3262 or email: [email protected]
Agenda Topics
The Big Picture
Value Based Pricing – Balancing Innovation and Affordability
Governments in an ever increasing number ofcountries are considering cost containment measuresto include ‘value based pricing’ as a way to controlescalating healthcare costs. Value considerations are already a precondition for reimbursement in countries such as Germany and Sweden, and are set to become part of the UK system in January 2014. The move is controversial, setting proponents, who see the opportunity for improved access and cost effectiveness against those who fear for the impact on the willingness and ability of life science companies todevelop vital new drugs. What will VBP look like, and will the benefits of VPB outweigh the potential risks?
Real World Evidence – Capturing the Valueof Pharma
With the advent of value based pricing comes theneed for life sciences companies to compile realworld evidence (RWE), in order to ‘prove’ the value of their products. The move to RWE has significant practical and strategic implications for life science companies: It will mean finding, integrating and analysing vast arrays of data and ensuring that this evidence is credible and able to meet the needs of multiple stockholders. What are the challenges of RWE, and how do companies prepare, and build RWE capabilities?
CEO Forum: Perspectives on Growth
With margins increasingly under pressure, thelong cherished exclusivity of many branded drugscoming to an end, and new competitors increasinglyencroaching in the industry, life science leadersmust consider and refine their strategies to stayahead of the game. What do the industry’s leadingCEOs see as the key risks and opportunities facingthe industry now and into the future? How are theydefining and articulating value, and how are theypositioning themselves for the challenges ahead?
The New Operating Models of Pharma
Radical reform in the way healthcare is delivered andpaid for have the potential to transform the operatingmodel and create new revenue streams for life science companies. The move to VBP affords life science companies the opportunity to maximiserevenues both from the product, and from the sale
of related health management services, whilst the new focus on ‘treatment pathways’ provides the opportunity for new services relating to prevention, treatment, and after care. In this space, however, life science companies will encounter players with expertise in data, in service delivery, and in technology who will compete for market share. Who will be the winners, how can life science compete, and what role can they play in these new markets?
Emerging Markets: Low-Income Countries – Philanthropy or Profit?
Even as an increasing number of countries from Brazilto China look to cut the prices they pay on medicines,along similar lines to their value conscious developedworld counterparts, life science companies are extending their reach into emerging markets which they view as a vital source of growth and innovation. They are also increasingly turning their attentions to low-income countries, and building reputations and relationships which will yield new patients and new growth markets in the longer term. Can life science companies make money in low-income countries? How can ‘social business’ approaches lead to long-term benefits and business in the future?
Reconfiguring the Supply Chain fora Patient Centred World
For too long relegated to the status of back officefunction, the supply chain is now taking its placecentre stage in the strategy of life science companieswho see the potential of efficiencies, and for value interms of a key differentiator in a competitive marketplace. What are the drivers of this change, and how are‘best in class’ companies reconfiguring their supplychains for an increasingly globalised, patient-centric,and value driven healthcare market?
Harnessing the Rewards of Culture,Diversity and Talent Across the Enterprise
The changes facing the industry will require asignificant shift in the culture, leadership skills andthe human resource needs of life science and device companies to enable them to meet the challenges they face head on, What are the qualities which will be required of leaders of tomorrow’s life sciences companies? What are the new skill sets which will be needed for life science companies to ensure they have the capabilities to meet these challenges, and what are the implications for organisational structures andcompany culture?
www.ft-live.com/pharmabio
REGISTRATION FORM
FT Global Pharmaceutical and Biotechnology Conference 20124-5 December 2012 | The Grange City Hotel, London
Event Enquiries and Registration
Michael Lundby
Tel +44 (0)20 7873 3837Fax +44 (0)20 7873 4204Email [email protected] www.ft-live.com/pharmabioPost FT Conferences, Financial Times Limited Number One Southwark Bridge London SE1 9HL
Sponsorship Enquiries
Gigs Thoukidides
Tel +44 (0) 20 7873 3262Email [email protected]
Terms & Conditions
The Financial Times Limited trading as Financial TimesConferences (“FTC”) will receive bookings subject to availabilityfor FTC events (“Events”) on receipt of this completed registration form accompanied by full payment details or via the submission of an online booking at www.ftconferences.com.
Upon FTC’s written (including online) communication to you of its acceptance of your booking for a place at an FTC Event there shall be a legally binding contract between FTC and you to whichthe terms and conditions are found in the Term's & Conditions footer link of http://www.ft-live.com/pharmabio
By submitting this Registration Form, you agree that you have read and accepted the terms and conditions found in the Term's & Conditions footer link of http://www.ft-live.com/pharmabio
The Fee does not include travel to or from the Event or anyaccommodation costs incurred.
Cancellation charges apply where cancellation is made bydelegates less than 30 days prior to the Event. Whilst our programs are correct at the time of going to press, in certain circumstances it may be necessary for FTC to alter the content, venue or timing of an Event. All delegates will benotified in advance of such changes.
DATA PROTECTION
The FT group take your privacy seriously. We collect and use your contact details to provide you with our information services, conduct market research and inform you about products and services. Please confirm your preferences below:
I do NOT wish to receive information about products andservices from the Financial Times preferences below
I do NOT wish to receive information by post about other FT group products and services or from carefully selected third parties
YES, I would like to receive information via electroniccommunication about other FT group products and services or from carefully selected third parties
FT Registered Office: Financial Times Limited,
Number One, Southwark Bridge, London SE1 9HL
Registered No: 227590
Venue & Accommodation
The Grange City Hotel, London 8-14 Cooper's RowLondon EC3N 2BQUnited Kingdom
Tel: +44 (0) 20 7863 3700
Fax: +44 (0) 20 7863 3701
Web: www.grangehotels.com
Delegate Details
PLEASE COMPLETE IN BLOCK CAPITALS
Please photocopy this form for registration of additional delegates
Mr/Mrs/Miss/Ms/Dr
First Name
Surname
Position
Department
Company/Organisation
Address
City Postcode
Country
Tel
Fax
Type of Business
Payment Options
For group booking discounts, please call +44 (0)20 7873 3837 or email [email protected]
Enclosed is a cheque made payable to Financial Times Limited (Ref: PB0612)Please see Event Enquiries and Registration section for postal address
Please charge my credit card
VISA MasterCard AMEX
Card No
Expiry Date
Card Holder’s Name
Card Billing Address
Signature Date
Contact Tel No for Card Holder Conference Code: PB0612
27/07/2012 - £996.00
28/09/2012 - £1195.00 01/11/2012 - £1495.00
31/10/2012 - £1395.00
